Company: OPGN
Filing Date: 2025-10-31
Form Type: 10-Q
Source: 0001829126-25-008771
Chunk: 3

Company: OPGEN INC
Filing Date: 2025-10-31
Form: 10-Q
Item: Part I, Item 1
Chunk 3
---
:

    Net cash used in investing activities

    -

    -

    Cash flows from financing activities:

    Proceeds from issuance of preferred stock, net of issuance costs

    -

    550,000

    Proceeds from short term insurance financing

    284,304

    300,926

    Payments on short term insurance financing

    (117,986
    )

    (30,093
    )
  
    Payments on finance lease obligations

    -

    (280
    )
  
    Net cash provided by financing activities

    166,318

    820,553

    Effects of exchange rates on cash

    -

    -

    Net decrease in cash, cash equivalents and restricted cash

    (479,019
    )

    (983,709
    )
  
    Cash and cash equivalents and restricted cash at beginning of period

    1,612,915

    1,454,085

    Cash and cash equivalents and restricted cash at end of period
     
    $
    1,133,896

    $
    470,376

    Supplemental disclosure of cash flow information

    Cash paid for interest
     
    $
    4,861

    $
    1,079

See accompanying notes to unaudited condensed consolidated financial statements.

4

OpGen, Inc. and Subsidiaries

Notes to Unaudited Condensed Consolidated Financial Statements

June 30, 2025

Note 1 – Organization

OpGen, Inc. (“OpGen” or the “Company”) was incorporated in Delaware in 2001. In April 2020, OpGen completed a business combination transaction with Curetis N.V., a public company with limited liability under the laws of the Netherlands, pursuant to which the Company acquired all the shares of Curetis GmbH, a private limited liability company organized under the laws of the Federal Republic of Germany (“Curetis”), and certain other assets and liabilities of Curetis N.V., including Ares Genetics GmbH (“Ares Genetics”), a wholly-owned subsidiary of Curetis.

From inception until November 2023, OpGen operated as a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. The Company, along with its subsidiaries, Curetis and Ares Genetics, developed and commercialized molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes and decrease the